Rockwell Medical, Inc. - Common Stock (RMTI)
7.4900
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 20th, 5:57 AM EDT
Detailed Quote
| Previous Close | 7.490 |
|---|---|
| Open | - |
| Bid | 7.100 |
| Ask | 8.600 |
| Day's Range | N/A - N/A |
| 52 Week Range | 4.885 - 12.90 |
| Volume | 200 |
| Market Cap | 703.23M |
| PE Ratio (TTM) | -41.61 |
| EPS (TTM) | -0.2 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 30,149 |
Chart
About Rockwell Medical, Inc. - Common Stock (RMTI)
Rockwell Medical is a biopharmaceutical company that focuses on developing and providing innovative treatments for patients with chronic kidney disease and end-stage renal disease. The company specializes in therapies aimed at addressing the complications associated with these conditions, particularly iron deficiency anemia. Rockwell Medical is engaged in the research and development of solutions that enhance the quality of life for patients undergoing dialysis and other renal care, aiming to improve patient outcomes through effective medical interventions. Read More
News & Press Releases
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026. The Company will issue a press release at 6:00 a.m. EST followed by a live webcast at 8:00 a.m. EST.
By Rockwell Medical · Via Business Wire · October 15, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company is exhibiting its hemodialysis concentrates portfolio in Booth #1049 at the American Society of Nephrology ("ASN") Kidney Week 2026, which will be held October 21-25 at the Colorado Convention Center in Denver, CO.
By Rockwell Medical · Via Business Wire · October 14, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Great Place to Work® and Fortune magazine named Rockwell Medical No. 16 out of 50 on the 2026 Fortune Best Workplaces in Manufacturing & ProductionTM List in the small & medium category. This marks the third consecutive year that Rockwell Medical has earned this recognition—climbing from No. 50 on the list in 2024 and No. 40 on the list in 2025—underscoring the Company’s continued progress in building an employee-validated culture where people are central to its success, understand the impact of their work, and have opportunities to contribute and grow.
By Rockwell Medical · Via Business Wire · October 7, 2026
Rockwell Medical (NASDAQ:RMTI) Posts Q1 Miss, But Profitability Roadmap Drives Pre-Market Optimismchartmill.com
Via Chartmill · May 7, 2026
Rockwell Medical Inc (NASDAQ:RMTI) Reports Q4 Revenue Miss but Highlights Margin Expansion and 2026 Profitability Outlookchartmill.com
Via Chartmill · March 26, 2026
Revenue grew 11% as automation and western expansion boosted margins and cash flow.
Via The Motley Fool · August 13, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2026.
By Rockwell Medical · Via Business Wire · August 13, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Brian Cox has joined the Company as Vice President, Quality and Regulatory Compliance.
By Rockwell Medical · Via Business Wire · July 22, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
By Rockwell Medical · Via Business Wire · July 20, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026. The Company will issue a press release at 6:00 a.m. ET followed by a live webcast at 8:00 a.m. ET.
By Rockwell Medical · Via Business Wire · July 16, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that its Board of Directors (the "Board") has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock (the "Reverse Stock Split"). The Board received approval at the Company's Annual Meeting of Stockholders on June 12, 2026 to approve and adopt an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock.
By Rockwell Medical · Via Business Wire · June 29, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has renewed and extended its product purchase agreement (the "Agreement") with aQua Dialysis, LLP, a leading independent provider of in-center hemodialysis and home dialysis services in Texas.
By Rockwell Medical · Via Business Wire · May 20, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a three-year product purchase agreement (the "Agreement") with Heritage Dialysis, a Michigan-based family-owned company comprised of dialysis professionals that specialize in providing home dialysis in skilled nursing facilities, assisted living and senior living communities, and patients' homes.
By Rockwell Medical · Via Business Wire · May 14, 2026
RMTI Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2026.
By Rockwell Medical · Via Business Wire · May 7, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET.
By Rockwell Medical · Via Business Wire · April 9, 2026

Rockwell Medical (RMTI) Earnings Call Transcript
Via The Motley Fool · March 26, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve months ended December 31, 2025.
By Rockwell Medical · Via Business Wire · March 26, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET.
By Rockwell Medical · Via Business Wire · February 26, 2026
Get insights into the top gainers and losers of Friday's after-hours session.chartmill.com
Via Chartmill · February 20, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has been certified as a Great Place to Work® for the fourth year in a row.
By Rockwell Medical · Via Business Wire · February 12, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · January 21, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
By Rockwell Medical · Via Business Wire · January 20, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.
By Rockwell Medical · Via Business Wire · January 12, 2026
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Amended and Restated Product Purchase Agreement (the "Amended Agreement") dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States (the "Customer") has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.
By Rockwell Medical · Via Business Wire · January 5, 2026